EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers

Bjørg Bolstad iD, Ragnar Hovland, Johan Bylund, Erik Rein-Hedin, Sandra Kuusk, Bjørn Klem, Pål Rongved iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00426-26 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Bjørg Bolstad und 6 weiteren Autor:innen. Beteiligte Einrichtung: AdjuTec Pharma AS, Oslo, Norway. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eurostars, Norges Forskningsråd, VINNOVA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

APC148 is a novel metallo-β-lactamase inhibitor with broad activity against Ambler class B enzymes, including NDM, VIM, and IMP. It is being developed for patients with serious infections caused by multidrug-resistant, gram-negative bacteria. APC148 is combined with the broad-spectrum β-lactam antibiotic meropenem and the serine-β-lactamase inhibitor avibactam, which targets Ambler class A, C, and some class D (OXA-48-like) enzymes. In combination with meropenem and avibactam, APC148 demonstrated superior in vitro activity against a global, multidrug-resistant collection of Enterobacterales, showing its promising activity against β-lactamase-producing pathogens. In this randomized, placebo-controlled, first-in-human study, the safety, tolerability, and pharmacokinetics of APC148 were evaluated in healthy adults. Single doses ranging from 50 mg to 760 mg APC148 were administered intravenously over 3 h to 46 participants across six dose groups. APC148 was well-tolerated at all dose levels. All adverse events were of mild intensity, and no serious adverse events or adverse events leading to study or treatment discontinuation occurred. The pharmacokinetics of APC148 were dose-proportional, with low plasma clearance, low-to-moderate volume of distribution, and a mean plasma half-life of 2.6 h. APC148 is well-tolerated and represents a promising candidate in the fight against antibiotic-resistant bacteria. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT06360640 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial AgentsHumansAdultFemaleMaleYoung AdultMiddle AgedHealthy VolunteersAzabicyclo Compoundsbeta-LactamasesMeropenemMicrobial Sensitivity TestsThienamycins

Stichwörter der Autor:innen

APC148metallo β-lactamasespharmacokineticsphase 1β-lactamase inhibitor

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesMeropenemavibactamThienamycins

Autor:innen und Institutionen

  • AdjuTec Pharma AS, Oslo, Norway.
  • Clinical Trial Consultants AB, Uppsala, Sweden.
  • Department of Surgical Sciences, Plastic Surgery, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Bjørg Bolstad, Pål Rongved

Förderung

  • Eurostars
  • Norges Forskningsråd
  • VINNOVA

Zitieren

APA

Bolstad, B., Hovland, R., Bylund, J., Rein-Hedin, E., Kuusk, S., Klem, B., & Rongved, P. (2026). Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00426-26

Vancouver

Bolstad B, Hovland R, Bylund J, Rein-Hedin E, Kuusk S, Klem B, et al. Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00426-26

BibTeX
@article{Bolstad2026,
  author = {Bolstad, Bjørg and Hovland, Ragnar and Bylund, Johan and Rein-Hedin, Erik and Kuusk, Sandra and Klem, Bjørn and Rongved, Pål},
  title = {Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00426-26}
}
Kostenlos starten →